ADVANZ PHARMA Holdco Limited (“ADVANZ PHARMA” or “the Company”), a UK headquartered global pharmaceutical company with a strategic focus on speciality, hospital, and rare disease medicines today announced the expansion of its specialty brands portfolio with the acquisition of certain APAC (excluding Japan and China) rights of Progynova® and Cyclo-Progynova® from Bayer.
Progynova is an oral hormone replacement therapy to treat signs and symptoms of estrogen deficiency and/or to prevent post-menopausal osteoporosis. Cyclo-Progynova* is a menstrual regulator for women of any age.**
ADVANZ PHARMA continues leveraging its commercial footprint and global partner network to bring specialty medicines to patients worldwide. The transaction follows the announcement in October 2023 that ADVANZ PHARMA signed an agreement to acquire Progynova® and Cyclo-Progynova® in selected countries in LATAM from Bayer.
